Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vitae Pharmaceuticals (VTAE) Ends 3Q With Cash Available Through 2016; Piper Jaffray Raises Price Target to $18
November 6, 2015 11:26 AM ESTPiper Jaffray reiterated an Overweight rating on Vitae Pharmaceuticals (NASDAQ: VTAE), and raised the price target to $18.00 (from $16.00), following the company's 3Q earnings report. Vitae ended 3Q:15 with $69 million, sufficient to fund the company through 2016. Lead candidate VTP-43742, inhibiting the RORt/IL-17 pathway, is currently in a multiple ascending dose trial in both healthy... More
Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c
November 6, 2015 8:30 AM ESTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More